REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Research/Paper
Back to Research Library
PubMedPreclinical

T cell receptor mimic CAR T cells targeting cathepsin G signal peptide.

Yan Jun, Shi Chunhua, Yang Guojun, Tian Ze, Torikai Hiroki, Sukhumalchandra Pariya, Peng Shaohua, Chang Edward, Cui Meng, Kerros Celine
Leukemia2025DOI: 10.1038/s41375-025-02652-0
cathepsin G signal peptideCG1

Quality Score

6/10

Citations

0

Subjects

Non-Human

PeptideVault Analysis

Study Design

Preclinical research is the foundation of the drug development pipeline. While these findings require human validation, they establish the mechanistic basis that informs dosing strategies, safety profiles, and target identification for future clinical work.

Our Assessment

Quality Assessment: 6/10 — This is a solidly conducted study with clear methodology and reasonable conclusions. Minor limitations exist (noted below) but don't undermine the core findings. The evidence here is reliable enough to inform both research direction and practical decision-making.

Findings in Context

These findings advance our understanding of cathepsin G signal peptide, CG1 in meaningful ways.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: A solid contribution to cathepsin G signal peptide, CG1 research. Worth reading alongside other studies on the same compounds for a balanced picture.

Key Findings

The study demonstrates the safety and efficacy of CG1/A2-targeting chimeric antigen receptor (CAR) T cells in targeting HLA-A2-restricted, cathepsin G-derived signal peptide CG1 in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML).

Limitations

The study is preclinical and has not been tested in human subjects yet. The safety and efficacy of the CAR T cells need to be confirmed through clinical trials.

PeptideVault Analysis

Highlighting the potential of CG1/A2-targeting CAR T cells as a novel immunotherapy approach in myeloid malignancies.

cathepsin G signal peptideCG1

Novel CAR T Cells Targeting Cathepsin G Signal Peptide Show Promise in Leukemia Treatment

Published: May 16, 2026 | Source: Leukemia (2025) | Category: cathepsin G signal peptide, CG1

Overview

A recent study published in Leukemia reveals the potential of chimeric antigen receptor (CAR) T cells targeting a specific signal peptide derived from cathepsin G (CG), known as CG1. This research offers new hope for treating acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) by leveraging an innovative immunotherapy approach.

Study Background

Immunotherapies have revolutionized cancer treatment, but the development of effective targets in myeloid malignancies has been challenging. The study builds on previous research where a T cell receptor mimic antibody targeting CG1 was developed and shown to be safe and efficacious against AML and CML. This new work aims to extend these findings by engineering CAR T cells that can recognize and target the same HLA-A2-restricted signal peptide, CG1.

What the Research Found

Researchers engineered CAR T cells using a T cell receptor mimic (TCR-m) specific for CG1/A2 complexes. These modified CAR T cells demonstrated high affinity for both CG1/A2 monomers and leukemia cells expressing this complex. The study showed that these CAR T cells were effective in preclinical models of AML and CML, indicating their potential as a therapeutic tool against these diseases.

What This Means for Peptide Users

While the findings are promising, it is important to note that this research has only been conducted in preclinical settings. For peptide users, particularly those involved in immunotherapy development or clinical trials, the study highlights a new direction in targeting myeloid malignancies through specific signal peptides. However, further validation and clinical testing are necessary before these CAR T cells can be used in patient care.

Limitations and Caveats

The primary limitation of this research is its preclinical nature; no human subjects have been involved yet. Additionally, the study focuses on HLA-A2-restricted CG1/A2 complexes, which limits applicability to patients with this specific genetic marker. The safety and efficacy profiles in humans remain unknown until clinical trials are conducted.

How This Compares to Previous Research

This work builds upon earlier studies that established the feasibility of targeting CG1 using TCR-m antibodies. Unlike those previous efforts, however, this study introduces a novel approach by utilizing CAR T cells engineered with the same specificity. While both methods show promise in preclinical settings, the use of CAR T cells may offer advantages such as enhanced persistence and anti-tumor activity.

Our Analysis

PeptideVault views this research positively but emphasizes the need for caution due to its preliminary stage. The innovative approach of targeting a signal peptide with CAR T cells represents an exciting development in cancer immunotherapy, particularly for myeloid malignancies where effective targets have been scarce. However, rigorous clinical validation is essential before these findings can be translated into practical medical applications.

Key Takeaways

  • Novel Target: CG1/A2 complexes represent a promising new target for CAR T cell therapy.
  • Preclinical Success: The study demonstrates efficacy in preclinical models of AML and CML.
  • Clinical Validation Needed: Further research is required to confirm safety and effectiveness in human patients.

Original Source

Citation: Yan Jun, Shi Chunhua, Yang Guojun et al. (2025). T cell receptor mimic CAR T cells targeting cathepsin G signal peptide.. Leukemia. DOI: 10.1038/s41375-025-02652-0

Access: https://pubmed.ncbi.nlm.nih.gov/40437170/

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Editor's Note

This analysis was written by the PeptideVault research team to make complex findings accessible to the peptide community. We encourage readers to review the source paper for full methodology and data. For more on cathepsin G signal peptide, explore our research guides.

Citation

Yan Jun, Shi Chunhua, Yang Guojun et al.. (2025). T cell receptor mimic CAR T cells targeting cathepsin G signal peptide.. Leukemia. https://doi.org/10.1038/s41375-025-02652-0

View full text on PubMed

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.